CD8A and myeloid sarcoma: It is tempting to speculate that the success of therapeutic targeting of this molecule for the treatment of MS not only relies on inhibition of T cell migration across the BBB but in parallel on prohibiting Ag-specific CD8+ T cell interactions with the brain endothelium and thus CD8+ T cell mediated BBB breakdown.